Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments
Susan Richter, Charlotte Steenblock, Alessa Fischer, Sandy Lemm, Christian G. Ziegler, Nicole Bechmann, Svenja Nölting, Jens Pietzsch, Martin Ullrich
Abstract
Lu]Lu-DOTA-TATE. Moreover, molecular pathways involved in NEN tumorigenesis and progression that mediate features of radioresistance and are particularly related to the stemness of cancer cells are discussed. Pharmacological inhibition of such pathways might result in radiosensitization or general complementary antitumor effects in patients with certain genetic, transcriptomic, or metabolic characteristics. Finally, we provide an overview of approved targeted agents that might be beneficial in combination with radionuclide therapies in the context of a personalized molecular profiling approach.